1. Home
  2. FSTR vs LUNG Comparison

FSTR vs LUNG Comparison

Compare FSTR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo L.B. Foster Company

FSTR

L.B. Foster Company

N/A

Current Price

$28.14

Market Cap

280.8M

Sector

Industrials

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.38

Market Cap

72.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSTR
LUNG
Founded
1902
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.8M
72.2M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
FSTR
LUNG
Price
$28.14
$1.38
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
$32.00
$5.38
AVG Volume (30 Days)
19.3K
711.1K
Earning Date
03-03-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
0.69
N/A
Revenue
$540,009,000.00
$90,497,000.00
Revenue This Year
$5.44
$6.20
Revenue Next Year
$3.05
$21.61
P/E Ratio
$40.75
N/A
Revenue Growth
1.74
8.01
52 Week Low
$17.16
$1.31
52 Week High
$32.63
$7.46

Technical Indicators

Market Signals
Indicator
FSTR
LUNG
Relative Strength Index (RSI) 44.93 38.39
Support Level $27.26 N/A
Resistance Level $29.72 $1.93
Average True Range (ATR) 1.17 0.16
MACD -0.05 -0.03
Stochastic Oscillator 42.07 5.88

Price Performance

Historical Comparison
FSTR
LUNG

About FSTR L.B. Foster Company

L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: